Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Zinc Supplementation in Shigella Patients
This study has been completed.
Sponsors and Collaborators: International Centre for Diarrhoeal Disease Research, Bangladesh
Karolinska Institutet
Information provided by: International Centre for Diarrhoeal Disease Research, Bangladesh
ClinicalTrials.gov Identifier: NCT00321126
  Purpose

Shigellosis is a major cause of morbidity and mortality in young children in Bangladesh and other developing countries. Further, the increasing emergence of resistance to a wide range of antibiotics is of great concern. Another major public health problem in Bangladesh is malnutrition, which is closely linked with shigellosis and with a high mortality. In Shigellosis, a heavy nutritional burden is placed on children and vital micronutrients such as vitamin A is lost in the urine. We recently found that the immune response in S. Flexneri infection was lower in children who were severely malnourished (weight-for-age≤65% as a percentage of the National Centre for Health Statistics median) when compared to children with weight-for-age from >65-75%. T cell responses were primarily affected with lowered CD4/CD8 ratios, lowered proliferative responses to T cell mitogens, Conconavalin A (ConA) and phytohaemagglutinin (PHA). However, proliferation of pheripheral blood mononuclear cells (PBMs) was lowered only in the presence of autologous plasma suggesting that a factor(s) in plasma, probably nutritional, rather than a defect in cells themselves was responsible. In children with S. dysenteriae 1 infection, proliferative responses to PHA were similarly lowered in the presence of autologous plasma but inhibition correlated to lowered transferring levels in plasma and not to the weight-for-age of the children. Also severely malnourished children with either S. flexneri or S. dysenteriae 1 infection were more severely ill. These findingings show that immunity in malnourishrd children with shigella infection is impaired which may lead to more severe illness. As zinc has profound effects on immunity as well as clinical outcome in diarrhoeal diseases, it is possible that zinc deficiency may be a factor in reducing immunity and increasing severity of acute illness in malnourished children with shigellosis. In this study, we will investigate the effect of zinc supplementation, in a double blind placebo controlled trial, on inflammatory responses, outcome of acute illness and growth following recovery from acute illness with S. flexneri infection.


Condition Intervention Phase
Testing Effect of Intervention
Drug: Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
Phase III

U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Official Title: Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery

Further study details as provided by International Centre for Diarrhoeal Disease Research, Bangladesh:

Primary Outcome Measures:
  • Age
  • Sex
  • Weight
  • Body Mass index
  • Duration of diarrhoea before admission
  • Stool volume
  • Dehydration status

Secondary Outcome Measures:
  • In blood: total and differential WBC counts,C-reactive protein, albumin, serum electrolytes and creatinine concentration
  • Quantitation of luminal neutriphils
  • Immune response
  • Duration of recovery
  • Presence of blood and mucous in stool
  • Weight gain
  • Length gain
  • Episodes of illness during follow-up

Estimated Enrollment: 56
Study Start Date: January 1999
Estimated Study Completion Date: April 2002
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   12 Months to 59 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between 12-59 months
  2. Moderate malnutrition (61-75% Weight / Age – NCHS Median)
  3. Duration of diarrhoea of 5 days
  4. Culture confirmed shigella spp in stool on enrolment

Exclusion Criteria:

  1. Measles infection in the past six months
  2. Presence of obvious systemic illnesses
  3. Severe malnutrition
  4. Residence in a location requiring a journey of>2 hour from the Dhaka Hospital of the ICDDR,B
  5. Refusal to give consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00321126

Sponsors and Collaborators
International Centre for Diarrhoeal Disease Research, Bangladesh
Karolinska Institutet
Investigators
Principal Investigator: Swapan Kumar Roy, MBBS, M.Sc, Ph. D ICDDR, B
  More Information

Publications indexed to this study:
Study ID Numbers: 97-020
Study First Received: May 2, 2006
Last Updated: May 2, 2006
ClinicalTrials.gov Identifier: NCT00321126  
Health Authority: Bangladesh: Ethical Review Committee

Keywords provided by International Centre for Diarrhoeal Disease Research, Bangladesh:
Zinc
Shigella
Children
Bangladesh

Study placed in the following topic categories:
Shigellosis
Zinc
Dysentery, Bacillary

Additional relevant MeSH terms:
Growth Substances
Physiological Effects of Drugs
Trace Elements
Micronutrients
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009